Physician profile
Neha Mathur
NPI 1821254483
$88,398.98
in general payments reported to CMS, 2019-2025
32 companies · $50K in 2025
The $50K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $57.28 · 2021: $554 · 2022: $1,662 · 2023: $3,704 · 2024: $32K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Travel and Lodging: $11K · Food and Beverage: $8,273 · Consulting Fee: $2,915 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,248.69 |
| Travel and Lodging | $11,000.53 |
| Food and Beverage | $8,273.34 |
| Consulting Fee | $2,915.00 |
| Education | $122.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $38,695.22 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $25,845.32 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $14,971.25 | 2022-2025 | Ibsrela |
| Abbvie INC. | $3,608.37 | 2019-2025 | |
| Janssen Biotech, INC. | $1,470.66 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $826.02 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.18 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $323.93 | 2022-2025 | Omvoh |
| Celgene Corporation | $252.27 | 2022-2024 | Zeposia |
| Pfizer INC. | $245.63 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $223.70 | 2022-2025 | Rebyota |
| Pharmacosmos Therapeutics INC. | $169.73 | 2023 | Monoferric |
| Neuraxis, INC. | $160.92 | 2025 | |
| Phathom Pharmaceuticals, INC. | $159.13 | 2024 | Voquezna |
| Histosonics, INC. | $150.00 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $128.30 | 2023 | Conmed Hemostasis, Conmed Biliary, Conmed Generators |
| Celltrion USA INC. | $126.35 | 2024-2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $114.14 | 2021-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $93.49 | 2024 | Tremfya |
| Shire North American Group INC | $82.38 | 2019 | |
| Madrigal Pharmaceuticals | $81.32 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $61.98 | 2025 | Zenpep |
| Boston Scientific Corporation | $57.74 | 2024 | Resolution 360 Clip |
| Braintree Laboratories, INC. | $36.99 | 2021-2022 | |
| Qol Medical, LLC | $34.19 | 2022 | |
| Ucb, INC. | $25.83 | 2019 | |
| Daiichi Sankyo INC. | $19.26 | 2019 | |
| Cook Medical LLC | $16.63 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.62 | 2022 | |
| Redhill Biopharma INC. | $13.85 | 2021 | |
| Fresenius Kabi USA, LLC | $13.37 | 2023 | Idacio |
| Allergan, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.